Top Global Pharmaceutical Companies Market gross is about USD 1,114 billion in the year 2015. The top 10 global pharmaceutical industries share is over 30% in 2015. These global pharmaceutical companies majorly located in the Us and Europe and offering products of s very wide range. These are the powerhouses of the research and development in life sciences.
The analysis of top 10 Global pharmaceutical companies based on rankings. The criteria of the ranking are based on revenue, contribution, annual growth, investment in R&D, expenses and income, and revenue per employee. The sum of six criteria is used to final score statics.
1) Johnson & Johnson (U.S.)
It ranked top in the list, this company have the highest revenue in the year 2015. This company has one of the largest R&D budgets. The most important reason is that product portfolio the top 3 drugs to the pharmaceutical revenue are (35.84%) was lowest in the list. The top 3 products of this company are Remicade, Stelara, and Zytiga. The combined revenue of this 3 products was USD 11,266 million in 2015.
2) Hoffmann-La Roche AG (Switzerland)
It had revenue of USD 50,111 million in 2015. The company had the highest R&D expenses of USD 9,972 million. But the company portfolio is narrow. Avastin, Herceptin, and Rituxan were top 3 drugs for Roche in 2015. All of these products were related to the oncology, the patent rights were going to expire ( Avastin and Herceptin are 2016, and Rituxan is 2019)
3) Pfizer Inc. (U.S.)
It had revenue about 48,851 million in 2015. The companies R&D expenses were USD 7,690% in 2015. The top 3 drugs of these company are contributing 27.09% to the company’s revenue. This company had one of the lowest ratios of revenue from its top 3 drugs , the highest selling drug is Prevnar has patent expiry is on 2016, which is helping company’s market position.
4) Novartis AG (Switzerland)
The total revenue of Novartis AG is USD 49,414 million in 2015. The company revenue is declined by 5.30% per year. This company invested USD 8,935 million in R&D IN 2015. The top 3 products offering 31.18% to the company’s pharmaceutical revenue in 2015. The top three products were Glivec, Gilenya, and Lucentis. The combined sales of this products are USD 9,494 million in 2015.Bayer AG (Germany)
5) Bayer AG (Germany)
Though its total revenue is higher than those of Roche, Pfizer, and Novartis but the revenue of its top three products is low USD 15,253 million in 2015. The revenue of top 3 drugs to total revenue was one of the lowest for Pfizer -33.72% in 2015. 6) Merck & Co., Inc. (U.S.)
6) Merck & Co., Inc. (U.S.)
It had total revenue is about of USD 39,498 million in 2015. The company invested USD 6,704 million in R&D in 2015, the revenue of top 3 drugs is one of the lowest for Merck (24.55% in 2015)
7) GlaxoSmithKline plc (U.K.)
It is the first U.K based company in this list. It had total revenue of USD 36,566 million in 2015. The company invested USD 5,441 million in R&D in 2015. This company had lowest top 3 drugs contribution of -21.50% in 2015.
8) Sanofi (France)
It is the first French company in this list. The company revenue is growing by 8.99% between 2014 and 2015 to reach USD 34,542 million in 2015. The company invested USD 5,092 million in R&D in 2015. The revenue of top 3 drugs is Lantus, Plavix, and Lovenox contributing only 29.06 to its revenue in 2015. The patents of all three products were expired in 2014.
9) Gilead Sciences, Inc. (U.S.)
It is having the highest growth rate in 2015. It is growing by 2014 and 2015 to reach USD 32,639 million in 2015. The top 3 drugs are Harvoni, Solvaldi, and Truvada contributed 55.48% of its revenue in 2015, the patient expiry of all three drugs were too long ( Harvoni- 2030, Sovaldi and truvada-2021) which is the helpful factor for the company’s rapid growth.
10) AstraZeneca plc (U.K.)
Its total revenue is about USD 23,641 million in 2015. The companies R&D investment is higher among all the list. The contribution of top 3 drugs is 46.14% to it’s in 2015. Crestor’s Nexium’s patents expire in 2016, and Symbicort expires in 2017.